A Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

November 15, 2022

Primary Completion Date

May 31, 2026

Study Completion Date

December 31, 2026

Conditions
Intrahepatic Cholangiocarcinoma (ICC)
Interventions
DRUG

ICP-192

ICP-192 is a round, uncoated tablet, 5mg, orally.

Trial Locations (44)

100021

NOT_YET_RECRUITING

Cancer Hospital, Chinese Academy of Medical Sciences, Beijing

100032

NOT_YET_RECRUITING

Peking Union Medical College Hospital, Beijing

100069

NOT_YET_RECRUITING

Beijing Youan Hosptital,Capital Medical University, Beijing

100142

NOT_YET_RECRUITING

Beijing Cancer Hospital, Beijing

100730

RECRUITING

Beijing Hospital, Beijing

110004

NOT_YET_RECRUITING

Shengjing Hospital of China Medical University, Shenyang

110042

NOT_YET_RECRUITING

Liaoning Cancer Hospital&Institute, Shenyang

150081

NOT_YET_RECRUITING

Harbin Medical University Cancer Hospital, Harbin

200123

NOT_YET_RECRUITING

ZhongShan Hospital, Shanghai

200433

NOT_YET_RECRUITING

The Third Affiliated Hospital of Naval Medical University, Shanghai

210000

NOT_YET_RECRUITING

The Affiliated Hospital of Nanjing University Meidical School, Nanjing

213000

NOT_YET_RECRUITING

Changzhou Tumor Hospital, Changzhou

214499

NOT_YET_RECRUITING

Jiangyin Renmin Hospital, Jiangyin

215004

NOT_YET_RECRUITING

The Second Affiliated Hospital of Soochow University, Suzhou

221009

NOT_YET_RECRUITING

Xuzhou Central Hospital, Xuzhou

230036

NOT_YET_RECRUITING

Anhui Provincial Hospital, Hefei

250012

RECRUITING

Qilu Hospital, Jinan

250013

RECRUITING

Jinan Central Hospital, Jinan

250117

NOT_YET_RECRUITING

Affiliated Cancer Hospital of Shandong First Medical University, Jinan

300060

NOT_YET_RECRUITING

Tianjin Cancer Hospital, Tianjin

310005

NOT_YET_RECRUITING

Zhejiang Cancer Hospital, Hangzhou

310009

NOT_YET_RECRUITING

Shulan(Hangzhou) Hospital, Hangzhou

NOT_YET_RECRUITING

The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou

330000

NOT_YET_RECRUITING

The Second Affiliated Hospital of Nanchang University, Nanchang

330029

NOT_YET_RECRUITING

Jiangxi Cancer Hospital, Nanchang

350001

NOT_YET_RECRUITING

Fujian Medical University Union Hospital, Fuzhou

350011

NOT_YET_RECRUITING

Fujian Cancer Hospital, Fujian

350025

NOT_YET_RECRUITING

Mengchao hepatobiliary Hospital of FuJian Medical university, Fuzhou

410002

NOT_YET_RECRUITING

Human Provincial People's Hospital, Changsha

410013

RECRUITING

Hunan Cancer Hospital, Changsha

NOT_YET_RECRUITING

The Third Xiangya Hospital of Central South Uninversity, Changsha

430062

NOT_YET_RECRUITING

Zhongnan Hospital of Wuhan University, Wuhan

430079

NOT_YET_RECRUITING

Hubei Cancer Hospital, Wuhan

450003

NOT_YET_RECRUITING

Henan Cancer Hospital, Zhengzhou

450066

NOT_YET_RECRUITING

First Affiliated Hospital of Zhengzhou University., Zhengzhou

510000

NOT_YET_RECRUITING

Sun Yat-sen Memorial Hospital, Guangzhou

510060

NOT_YET_RECRUITING

Sun Yat-sen University Cancer Center, Guangzhou

510280

RECRUITING

ZhuJiang Hospital of Southern Medical University, Guangzhou

528000

NOT_YET_RECRUITING

Foshan First People's Hospital, Foshan

610041

NOT_YET_RECRUITING

Sichuan Cancer Hospital, Chengdu

NOT_YET_RECRUITING

West China Hospital of Sichuan University, Chengdu

710038

NOT_YET_RECRUITING

Tangdu Hospital of the Fourth Military Medical University, Xi'an

750004

NOT_YET_RECRUITING

General Hospital of Ningxia Medical University, Yinchuan

050011

NOT_YET_RECRUITING

Hebei Medical University Fourth Hospital, Shijiazhuang

All Listed Sponsors
lead

Beijing InnoCare Pharma Tech Co., Ltd.

INDUSTRY